Technical Analysis for CCXI - ChemoCentryx, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical CCXI trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 1.88% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.88% | |
Reversal New Lows Setup | Bearish Swing Setup | 1.88% | |
Outside Day | Range Expansion | 1.88% | |
Oversold Stochastic | Weakness | 1.88% | |
Outside Day | Range Expansion | -4.51% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 9 hours ago |
Up 3% | about 12 hours ago |
Up 2% | about 12 hours ago |
Up 1% | about 12 hours ago |
Down 5% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2021
ChemoCentryx, Inc. Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Clinical Development Autoimmune Diseases Monoclonal Antibodies Autoimmune Disease Inflammatory Disease Rheumatoid Arthritis Kidney Disease Blastoma Inflammatory Bowel Disease Glioblastoma Dermatitis Renal Disease Atopic Dermatitis Diabetic Nephropathy Immunosuppressants Related Disorders Inflammatory Disorders Biotie Therapies Glioblastoma Multiforme Chronic Hepatitis Janus Kinase Inhibitor Vasculitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 70.22 |
52 Week Low | 44.68 |
Average Volume | 433,585 |
200-Day Moving Average | 56.67 |
50-Day Moving Average | 58.14 |
20-Day Moving Average | 51.53 |
10-Day Moving Average | 49.04 |
Average True Range | 2.86 |
ADX | 28.05 |
+DI | 10.91 |
-DI | 24.59 |
Chandelier Exit (Long, 3 ATRs ) | 51.01 |
Chandelier Exit (Short, 3 ATRs ) | 54.57 |
Upper Bollinger Band | 58.35 |
Lower Bollinger Band | 44.71 |
Percent B (%b) | 0.18 |
BandWidth | 26.47 |
MACD Line | -3.02 |
MACD Signal Line | -2.91 |
MACD Histogram | -0.1157 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 50.13 | ||||
Resistance 3 (R3) | 50.11 | 49.11 | 49.64 | ||
Resistance 2 (R2) | 49.11 | 48.35 | 49.12 | 49.48 | |
Resistance 1 (R1) | 48.14 | 47.89 | 48.62 | 48.16 | 49.31 |
Pivot Point | 47.14 | 47.14 | 47.38 | 47.15 | 47.14 |
Support 1 (S1) | 46.17 | 46.38 | 46.66 | 46.20 | 45.05 |
Support 2 (S2) | 45.17 | 45.92 | 45.18 | 44.88 | |
Support 3 (S3) | 44.20 | 45.17 | 44.72 | ||
Support 4 (S4) | 44.23 |